In the ATTEMPT-CVD trial presented at the ESC Congress 2015, a strategy of angiotensin II-receptor blocker (ARB) therapy with telmisartan was compared with a standard non-ARB strategy in a total of 1,228 patients with hypertension in Japan. In this multicentre, open-label, randomized trial, telmisartan therapy was associated with a smaller increase in plasma brain natriuretic peptide level, and a greater decrease in urinary albumin creatinine ratio than non-ARB treatment, despite similar control of blood pressure. These parameters are known to be strong biomarkers of cardiovascular and renal risk; however, the rate of cardiovascular events did not differ significantly between the two groups.
References
Ogawa, H. et al. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): biomarker study. Eur. J. Prevent. Cardiol. 10.1177/2047487315603221
Rights and permissions
About this article
Cite this article
Effectiveness of angiotensin II-receptor blockade in cardiovascular disease prevention. Nat Rev Cardiol 12, 623 (2015). https://doi.org/10.1038/nrcardio.2015.151
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.151